Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer

被引：0
|
作者：
Makarem, M. [1 ]
Ricciuti, B. [1 ]
Alessi, J. V. [1 ]
Pecci, F. [1 ]
Di Federico, A. [1 ]
Gandhi, M. [1 ]
Janne, P. A. [1 ]
Awad, M. M. [1 ]
Rotow, J. K. [1 ]
机构：
[1] Lowe Ctr Thorac Oncol, Dana Farber Canc Inst, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.980
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2198P
引用
收藏
页码：S1136 / S1136
页数：1
相关论文
共 50 条
  • [1] HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
    Yu, Xin
    Ji, Xianxiu
    Su, Chunxia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer
    Zhang, Shirong
    Wang, Wenxian
    Xu, Chunwei
    Zhang, Yongchang
    Cai, Xiuyu
    Wang, Qian
    Song, Zhengbo
    Li, Ziming
    Yu, Jinpu
    Zhong, Wenzhao
    Wang, Zhijie
    Liu, Jingjing
    Liu, Anwen
    Li, Wen
    Zhan, Ping
    Liu, Hongbing
    Lv, Tangfeng
    Miao, Liyun
    Min, Lingfeng
    Lin, Gen
    Huang, Long
    Yuan, Jingping
    Jiang, Zhansheng
    Pu, Xingxiang
    Rao, Chuangzhou
    Lv, Dongqing
    Yu, Zongyang
    Li, Xiaoyan
    Tang, Chuanhao
    Zhou, Chengzhi
    Zhang, Junping
    Guo, Hui
    Chu, Qian
    Meng, Rui
    Liu, Xuewen
    Wu, Jingxun
    Zhou, Jin
    Zhu, Zhengfei
    Pan, Weiwei
    Dong, Xiaowei
    Pang, Fei
    Wang, Kai
    Yao, Chao
    Lin, Guomin
    Li, Site
    Yang, Zhi
    Luo, Jiancheng
    Jia, Hongtao
    Nie, Xiuqing
    Wang, Liping
    THORACIC CANCER, 2023, 14 (01) : 91 - 104
  • [3] Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
    Bu, Shi
    Wang, Rui
    Pan, Yunjian
    Yu, Su
    Shen, Xuxia
    Li, Yuan
    Sun, Yihua
    Chen, Haiquan
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (01) : 291 - 297
  • [4] Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
    Shi Bu
    Rui Wang
    Yunjian Pan
    Su Yu
    Xuxia Shen
    Yuan Li
    Yihua Sun
    Haiquan Chen
    Annals of Surgical Oncology, 2017, 24 : 291 - 297
  • [5] Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer
    Hamaji, Masatsugu
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Terada, Kazuhiro
    Yoshizawa, Akihiko
    Kikuchi, Ryutaro
    Sakaguchi, Yasuto
    Sonobe, Makoto
    Muranishi, Yusuke
    Miyahara, Ryo
    Motoyama, Hideki
    Omasa, Mitsugu
    Hamaji, Masatsugu
    Date, Hiroshi
    JOURNAL OF THORACIC DISEASE, 2024, 16 (09)
  • [6] Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
    Conroy, Michael R.
    Dennehy, Colum
    Forde, Patrick M.
    LUNG CANCER, 2023, 183
  • [7] PATIENT EXPERIENCE OF IMMUNE CHECKPOINT INHIBITOR THERAPY FOR NON-SMALL CELL LUNG CANCER
    Williams, Loretta A.
    Whisenant, Meagan
    Malveaux, Donna
    Singhi, Eric K.
    Altan, Mehmet
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [8] Immune Checkpoint Therapy in Non-Small Cell Lung Cancer
    Marrone, Kristen A.
    Brahmer, Julie R.
    CANCER JOURNAL, 2016, 22 (02): : 81 - 91
  • [9] Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy
    Lee, Ji Hyun
    Kang, Danbee
    Ahn, Jin Seok
    Guallar, Eliseo
    Cho, Juhee
    Lee, Ho Yun
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2023, 14 (06) : 2898 - 2907
  • [10] Clinicopathologic and molecular characteristics in ERBB2 (HER2)-altered non-small cell lung cancer
    Lee, Y.
    Lee, B.
    Choi, Y.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S151 - S152
12345